Voyager Therapeutics, Inc. VYGR 深 滬
已收盤 07-02 16:00:00 美东时间
3.78
+0.180
+5.00%
華盛通- 最 高3.905
- 今 開3.62
- 成交量 111.96万股
- 最 低 3.575
- 昨 收 3.60
- 總市值 2.28亿
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 1.85%
- 52周最低 2.8838
- 委 比 68.83%
- 總股本 6042.13万
- 歷史最高 31.91
- 量 比 1.26
- 振 幅 9.17%
- 歷史最低 2.46
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics CEO Alfred W. Sandrock Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The webcast will be available on June 15, 2026, at 7:00 a.m. ET on the Company’s investor website and archived for 30 days. Voyager Therapeutics focuses on using human genetics to treat neurological diseases, with programs targeting Alzheimer’s, Parkinson’s, ALS, and...
06-11 20:01
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy
The latest announcement is out from Voyager Therapeutics ( ($VYGR) ). On June 1...
06-01 20:43
Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's Disease
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its
06-01 20:02
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics reported positive 3-month GLP toxicology data for VY1706, a tau-silencing gene therapy for Alzheimer's disease, showing up to 64% reduction in tau protein in non-human primates. The IND application for VY1706 is on track for Q2 2026, with clinical trials expected to begin in H2 2026. The company also highlighted advancements in capsid innovation, immune evasion, and manufacturing capabilities across multiple gene therapy prog...
05-13 10:01
Neurocrine Friedreich ataxia asset granted FDA orphan status
The US FDA has granted orphan drug designation to Neurocrine Biosciences' (NBIX) NBIB-223 (frataxin) for the treatment of Friedreich ataxia. Therapies with orphan status have a potential seven years o...
05-08 00:54
Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge
Voyager Therapeutics (VYGR) announced on Tuesday in an SEC Form 8-K filing that its CFO, Nathan Jorgensen, has resigned, effective May 8, 2026, to take up a new opportunity. The Board has appointed Ro...
04-22 04:56
Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes
Voyager Therapeutics ( ($VYGR) ) has shared an update. On April 15, 2026, Voyag...
04-22 04:40
Voyager Therapeutics CFO Nathan Jorgensen Resigns, Effective April May 8
https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000110465926045997/tm2612325d1_8k.htm
04-22 04:38
Amazon launches AI research tool to speed early-stage drug discovery
Amazon launches AI research tool to speed early-stage drug discovery By Sahil Pandey and Puyaan Singh April 14 (Reuters) - Amazon's AMZN.O cloud unit on Tuesday launched Amazon Bio Discovery, an artificial intelligence application designed to speed early-stage drug discovery by allowing scientists
04-14 22:31
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
